-
Early Health Outcomes Model on the Impact of Trimodulin in the Management of Patients With Severe Community-Acquired Pneumonia on Invasive Mechanical Ventilation Based on the CIGMA Phase 2 Randomized Placebo-Controlled Trial
Mar 10, 2025, 14:00 PM -
Real World Healthcare Resource Utilization (HRU) and Costs Associated With Mantle Cell Lymphoma (MCL) Therapies in the Frontline (1L) and Relapsed/Refractory (R/R) Setting
Mar 10, 2025, 14:00 PM -
Is It Time to Rethink Proxy-Reporting? Feasibility and Psychometric Considerations for Creating ObsROs That Adhere to Patient-Focused Drug Development (PFDD) Fit-for-Purpose Guidance
Mar 10, 2025, 14:00 PM -
Drug Pricing Differentials Across Therapy Areas in EU4, UK, and US
Mar 10, 2025, 14:00 PM -
Trends and Disparities in Weight Loss Activities Among Adults With Prediabetes and Obesity in the United States: 2009-2020
Mar 10, 2025, 14:00 PM -
Guidance for the Role of Key Opinion Leaders in the Identification and Validation of Treatment Effect Modifiers and Prognostic Variables in Indirect Treatment Comparisons
Mar 10, 2025, 14:00 PM -
Could Offering Physiotherapy Services in Emergency Departments Improve Patients’ Quality of Life While Reducing Healthcare Costs?
Mar 10, 2025, 14:00 PM -
Characterizing the Experience of Excessive Daytime Sleepiness in Patients with Idiopathic Hypersomnia: Implications for Measuring Daytime Sleepiness with the Epworth Sleepiness Scale in a Clinical Trial (NCT05156047)
Mar 10, 2025, 14:00 PM -
Sizing Up the Gap: Evaluating Sample Size Justification in Prospective Real-World Studies
Mar 10, 2025, 14:00 PM -
Reporting Standards in Predictive Modeling of Cancer Outcomes: An Umbrella Review of Adherence to the TRIPOD SR MA Reporting Guideline
Mar 10, 2025, 14:00 PM -
Assessability of Single-Arm Studies (SAT) Under Joint Clinical Assessment (JCA): Whether Drugs Assessed With SAT in the Last Years Would Fit Under the New EU HTA Framework?
Mar 10, 2025, 14:00 PM -
Inclusion of Health-Related Quality of Life (HRQoL) and Other Patient-Reported Outcomes (PROs) in the United States Food and Drug Administration (FDA) Labels
Mar 10, 2025, 14:00 PM -
Prospective, Comparative Study Between Fully-Automated and Semi-Automated Whole Blood Processing Systems in a Colombian Blood Bank Center
Mar 10, 2025, 14:00 PM -
Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Degludec for the Treatment of Patients With Type 2 Diabetes Mellitus in China
Mar 10, 2025, 14:00 PM -
Improving the Face Validity and Clinical Relevance of a Cancer Epidemiology Microsimulation Model Using a Novel Advisory Group Approach
Mar 10, 2025, 14:00 PM -
Association Between Caregiver Quality of Life and the Care Provided to Adults With Severe Visual Impairments: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
A Structured Literature Review on Survival, Complications, Disease Transformation, Treatment Pattern and Unmet Need Among Patients With Essential Thrombocythemia
Mar 10, 2025, 14:00 PM -
Trends in FDA Approvals of Cardiovascular Drugs from 1980 to 2024
Mar 10, 2025, 14:00 PM -
Costs of Alzheimer's Disease and Related Dementia among Medicare Beneficiaries in the United States
Mar 10, 2025, 14:00 PM -
Baseline Risk of Hospitalization and Mortality in High-Risk Subgroups of a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review
Mar 10, 2025, 14:00 PM